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ABSTRACT
Acute transfusion reactions (ATRs) are significantly rel-
evant to the morbidity and mortality of patients. ATRs 
are mostly not severe and rarely cause severe conditions, 
including anaphylactic shock. The aim of this study was 
to clarify the frequency of ATRs and the time of event 
occurrence. A total of 18,745 transfusions were adminis-
tered to 11,718 patients during a 3-year period. Adverse 
reactions including at least one sign or symptom were 
collected through a report system in 143 of 2,478 (5.7%) 
platelet concentrate transfusions, 105 of 6,629 (1.6%) 
red blood cell component transfusions and 51 of 2,307 
(2.2%) fresh frozen plasma transfusions. Allergic signs 
and symptoms accounted for 70% of all adverse events. 
Severe signs and symptoms were observed in 7.1% of 
patients. These events appeared significantly earlier than 
those of non-severe signs and symptoms (median time 
20 min vs 100 min, P < 0.05). For patients who have had 
repetitive transfusion-associated adverse events, preven-
tive treatments for adverse events should be proactively 
promoted.
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Transfusion-associated adverse events are mainly im-
munological acute transfusion reactions (ATRs). It is 
known that the distribution of signs and symptoms differ 
according to the types of blood components, numbers of 
transfusions, and patient’s condition.1–3 ATRs are mostly 
not severe but rarely cause severe diseases including 
transfusion-related acute lung injury (TRALI) and ana-
phylactic shock. Thus, it is important for health profes-
sionals to monitor patients during and after transfusion. 
 It is essential to establish a system for monitoring, 
recording and reporting adverse reactions caused by 
blood transfusion in each hospital, thereby contributing 
to the National Hemovigilance System in Japan. All 
medical institutions report adverse events following 
transfusion to the Japanese Red Cross Society if they 
recognize that the event is due to the transfusion itself. 
However, there are some problems associated with this 
self-reporting system; e.g. mild adverse events may not 
be reported.4 
 We constructed a system to monitor all patients 
who received transfusion and collected data regarding 
post-transfusion adverse reactions and event occurrence 
times.5 The aim of this study was to clarify the frequen-
cy of ATRs and the time to event occurrence.
MATERIALS AND METHODS
All patients who received transfusion at our facility 
within a 3-year period from January 2014 to December 
2016 were included in this retrospective study. A trans-
fusion was defined as an episode of transfusion of any 
blood component, regardless of dose or volume trans-
fused. All blood components, i.e., leukocyte-reduced red 
blood cell (RBC-LR), fresh frozen plasma (FFP-LR), 
and platelet concentrate (PC-LR), were provided by the 
Japanese Red Cross Blood Center. The following data 
were collected for all study subjects: age, gender, clinical 
department, signs and symptoms of adverse reactions, 
and event occurrence time.
 The transfusion-related signs and symptoms report-
ed were based on the Japanese Society of Transfusion 
Medicine and Cell Therapy definition of hemovigilance. 
Respiratory distress, hypotension, disturbance of con-
sciousness and hemoglobinuria were defined as severe 
signs and symptoms. This study was approved by the 
Ethics Committee at Tottori University Faculty of Medi-
cine (approval number: 1706A060).
Statistical analysis
Comparisons among qualitative variables (categorical 
data) were performed using Pearson’s chi-square test. 
A p value of less than 0.05 was considered significant. 
Time to event occurrence was analyzed with the Krus-
kal-Wallis test and Mann-Whitney U test. All statistical 
analyses were performed using SPSS version 16.0 (IBM, 
Armonk, NY).
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RESULTS
Frequency of ATRs
Between January 2014 and December 2016, a total of 
18,745 transfusions were administered to 11,718 patients. 
Blood components administered were 3,728 PC-LRs, 
10,246 RBC-LRs and 4,478 FFP-LRs. No differences in 
age and gender were found between patients for whom 
ATRs were reported and those for whom ATRs were 
not reported. ATRs having at least one sign or symp-
tom were 143 of 2,478 (5.7%) PC-LR transfusions, 105 
of 6,629 (1.6%) RBC-LR transfusions, and 51 of 2,307 
(2.2%) FFP-LR transfusions. The frequency of ATRs in 
PC-LR transfusions were significantly higher than those 
in RBC-LR and FFP-LR transfusions (chi-squared test, 
P < 0.05). 
Frequency of signs and symptoms reported
The frequency of signs and symptoms are shown in Ta-
ble 1. Allergic signs and symptoms including urticaria, 
pruritus and skin rash accounted for 70% of all signs 
and symptoms. PC-LR and FFP-LR showed high fre-
quencies of 80.7% and 83.1%, respectively, while RBC-
LR showed only 37.1%. On the contrary, fever, tachycar-
dia and hypertension were more frequent with RBC-LR 
than PC-LR and FFP-LR. Severe signs and symptoms 
(respiratory distress, hypotension, disturbance of con-
sciousness and hemoglobinuria) comprised 7.1% of all 
signs and symptoms.
Time to event occurrence
We evaluated the time from initiation of transfusion to 
the occurrence of signs and symptoms (Fig. 1). There 
was no significant difference among blood components 
(100 min vs 100 min vs 102.5 min, P = 0.19, Krus-
kal-Wallis test). Severe signs and symptoms appeared 
significantly earlier than non-severe ones (20 min vs 100 
min, P < 0.01, Mann-Whitney U test).
DISCUSSION
Blood transfusion therapy is an effective and indispens-
able treatment, but adverse events such as infectious 
diseases and immune reactions cannot be completely 
avoided. The risk factors of severe transfusion-related 
diseases including TRALI and anaphylactic shock de-
pend on patient’s disease, number of transfusions, and 
history of adverse events.6–9 Thus, it is necessary to list 
the patients who have ever had signs and symptoms after 
transfusion. We constructed a system of transfusion-as-
sociated signs and symptoms to be reported for all 
transfused patients, which made it possible to accurately 
assess the frequency of adverse reactions.5
 The frequency of adverse events with all blood prod-
ucts in the current study was higher than those in other 
facilities.1–3, 10–12 This is because even minor symptoms 
are fully reported in our facility and there are many pa-
tients who had adverse events repetitively, especially in 
the departments of hematology and pediatrics, in which 
blood transfusions were repeated in patients, exposing 
Table 1. Frequency of acute transfusion reactions
RBC-LR FFP-LR PC-LR Total
Transfusions 6,629 (100) 2,307 (100) 2,487 (100) 11,423 (100)
Adverse Reactions 105 (1.6) 51 (2.2) 143 (5.7*) 299 (2.6)
Signs and Symptoms 121 (100) 77 (100) 207 (100) 405 (100)
Urticaria 28 (23.1) 40 (51.9) 91 (44.0) 159 (39.3)
Pruritus 12 (9.9) 18 (23.4) 54 (26.1) 84 (20.7)
Skin rash 5 (4.1) 6 (7.8) 22 (10.6) 33 (8.1)
Fever 30 (24.8) 1 (1.3) 11 (5.3) 42 (10.4)
Feverishness 5 (4.1) 0 (0.0) 6 (2.9) 11 (2.7)
Hypotension 5 (4.1) 5 (6.5) 5 (2.4) 15 (3.7)
Nausea/vomiting 7 (5.8) 1 (1.3) 5 (2.4) 13 (3.2)
Respiratory distress 5 (4.1) 2 (2.6) 3 (1.4) 10 (2.5)
Tachycardia 8 (6.6) 2 (2.6) 0 (0.0) 10 (2.5)
Hypertension 5 (4.1) 1 (1.3) 0 (0.0) 6 (1.5)
Chill/rigor 4 (3.3) 1 (1.3) 5 (2.4) 10 (2.5)
Vein pain 5 (4.1) 0 (0.0) 0 (0.0) 5 (1.2)
Others 1 (0.8) 0 (0.0) 2 (1.0) 3 (0.7)
Disturbance of consciousness 0 (0.0) 0 (0.0) 3 (1.4) 3 (0.7)
Hemoglobinuria 1 (0.8) 0 (0.0) 0 (0.0) 1 (0.2)
Values are expressed as numbers with percent in parentheses. The underlined items are defined as severe signs and symptoms. *P < 0.05, 
Chi-squared test. FFP, fresh frozen plasma; LR, leukocyte-reduced; PC, platelet concentrate; RBC, red blood cell. 
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them to the plasma components of multiple donors.6, 7 In 
addition, prophylactic administration was infrequent and 
the use of washed blood components was rare. There are 
some reports that prophylactic administration and use of 
washed blood components are effective for prevention 
of allergic transfusion reactions.13, 14 Because history of 
adverse events is one of the risk factors for severe trans-
fusion-related disease for patients who had recurrent ad-
verse events, even with mild symptoms, these treatments 
should be enforced to prevent severe transfusion-related 
diseases.
 There was no significant difference in event oc-
currence times among blood components, but severe 
signs and symptoms appeared significantly earlier than 
non-severe ones. However, fatal transfusion-related 
events were not reported. There were cases in which 
adverse reactions occurred after 10 hours or more; it 
is therefore necessary to be vigilant during and after 
transfusion. These data may be useful to determine the 
observation time after blood transfusion at the outpatient 
clinic or at home. The 95th percentile of severe signs 
and symptoms occurrence time was 130 min, suggesting 
that we should observe patients for at least 2 hours after 
starting blood transfusion.
 In conclusion, a high frequency of transfusion-re-
lated signs and symptoms was found through the report 
system. For patients who have transfusion-associated 
adverse events repetitively, the use of prophylactic med-
ications or washed blood components and preventive 
treatments for adverse events should be proactively pro-
moted. 
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Fig. 1. Comparison of times from transfusion start to event oc-
currence (A) among blood components and (B) between severe 
and non-severe signs and symptoms. Respiratory distress, hypo-
tension, disturbance of consciousness and hemoglobinuria are 
defined as severe signs and symptoms *P < 0.05, Mann-Whitney 
U test. FFP, fresh frozen plasma; LR, leukocyte-reduced; PC, 
platelet concentrate; RBC, red blood cell.
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